{
  "id": "5e3c6850b5b409ea5300001f",
  "type": "yesno",
  "question": "Is bortezomib a Proteasome inhibitor?",
  "ideal_answer": "The proteasome inhibitor bortezomib is effective for a variety of tumors, but not for GBM. Proteasome inhibitor bortezomib",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26288836",
    "http://www.ncbi.nlm.nih.gov/pubmed/22702336",
    "http://www.ncbi.nlm.nih.gov/pubmed/28409734",
    "http://www.ncbi.nlm.nih.gov/pubmed/16278210",
    "http://www.ncbi.nlm.nih.gov/pubmed/31088925",
    "http://www.ncbi.nlm.nih.gov/pubmed/22027222",
    "http://www.ncbi.nlm.nih.gov/pubmed/21247388",
    "http://www.ncbi.nlm.nih.gov/pubmed/22216088",
    "http://www.ncbi.nlm.nih.gov/pubmed/28860152",
    "http://www.ncbi.nlm.nih.gov/pubmed/28317148"
  ],
  "snippets": [
    {
      "text": "The proteasome-inhibitor bortezomib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28317148",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The proteasome inhibitor bortezomib is effective for a variety of tumors, but not for GBM. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28409734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteasome inhibitor bortezomib ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28860152",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The proteasome inhibitor bortezomib, registered for Multiple Myeloma treatment, is currently explored for activity in solid tumors including non-small cell lung cancer (NSCLC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22702336",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The proteasome inhibitor bortezomib (also known as Velcade and PS-341) is a clinically effective antineoplastic drug that is FDA approved for treatment of hematologic malignancies such as multiple myeloma and mantle cell lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088925",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21247388",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The proteasome inhibitor bortezomib is emerging as a potent anti-cancer agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16278210",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bortezomib (Velcade\u2122) is a reversible proteasome inhibitor that is approved for the treatment of multiple myeloma (MM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22216088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26288836",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}